Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Enzymatica AB's annualized positive value of Interest Expense for the quarter that ended in Jun. 2026 was €0.09 Mil. Enzymatica AB's average total debt for the quarter that ended in Jun. 2026 was €0.68 Mil. Therefore, Enzymatica AB's annualized Effective Interest Rate on Debt % for the quarter that ended in Jun. 2026 was 13.60%.
Enzymatica AB (FRA:EN9) Effective Interest Rate on Debt % Explanation
Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.
Enzymatica AB Effective Interest Rate on Debt % Related Terms
Enzymatica AB Effective Interest Rate on Debt % Historical Data
* Premium members only.
The historical data trend for Enzymatica AB's Effective Interest Rate on Debt % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzymatica AB Effective Interest Rate on Debt % Chart
FRA:EN9 vs ZTS: Effective Interest Rate on Debt % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzymatica AB Effective Interest Rate on Debt % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Effective Interest Rate on Debt % distribution charts can be found below:
* The bar in red indicates where Enzymatica AB's Effective Interest Rate on Debt % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data,
the Interest Expense data used here is four times the quarterly (Jun. 2026) interest expense data.
Effective Interest Rate on Debt % is displayed in the 30-year financial page.
What does a Effective Interest Rate on Debt % of 13.60% mean?
Enzymatica AB (FRA:EN9) has a Effective Interest Rate on Debt % of 13.60% as of Jun. 2026. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Enzymatica AB and its competitors.
Is Enzymatica AB's Effective Interest Rate on Debt % too high?
Enzymatica AB's current Effective Interest Rate on Debt % is 13.60%. Overall, Enzymatica AB has a GF Score™ of 42/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Effective Interest Rate on Debt % compare to ZTS?
Enzymatica AB's Effective Interest Rate on Debt % of 13.60% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Effective Interest Rate on Debt % for a Drug Manufacturers company?
A good Effective Interest Rate on Debt % depends on the Drug Manufacturers industry context. However, Effective Interest Rate on Debt % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Effective Interest Rate on Debt % mean?
A high Effective Interest Rate on Debt % can signal that a stock is expensive relative to its fundamentals. Effective interest rate on debt is the rate a company actually pays on its debt. View historical data on Enzymatica AB and its competitors. Enzymatica AB's current Effective Interest Rate on Debt % is 13.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.17, compared to a current price of €0.14 — trading 18.8% below its estimated fair value. The current Effective Interest Rate on Debt % is 13.60%. Enzymatica AB's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Effective Interest Rate on Debt % calculated?
Effective Interest Rate on Debt % is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current Effective Interest Rate on Debt % is 13.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enzymatica AB (FRA:EN9) Overvalued in 2026?
Based on GuruFocus' analysis, Enzymatica AB stock appears to be undervalued.
The current stock price of €0.14 is trading 18.8% below its estimated GF Value™ of €0.17.
GuruFocus considers Enzymatica AB to be Modestly Undervalued.
Key valuation signals for FRA:EN9:
Effective Interest Rate on Debt %: 13.60%
GF Value™: €0.17 vs. price of €0.14 (18.8% below fair value)
No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
42GF Score
Get the complete analysis for FRA:EN9
Effective Interest Rate on Debt % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EN9 has been successfully added to your 
